Limitations on human rights: Are they justifiable to reduce the burden of TB in the era of MDR- and XDR-TB?

Health and Human Rights

Volumn 10, Issue 2, 2009, Pages 121-126

  Boggio, Andrea ^a   Zignol, Matteo ^b   Jaramillo, Ernesto ^b   Nunn, Paul ^b   Pinet, Geneviève ^b   Raviglione, Mario ^b  

^a BRYANT UNIVERSITY   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

CAUSE OF DEATH; DISEASE CONTROL; DISEASE TREATMENT; EPIDEMIOLOGY; HUMAN RIGHTS; INTERNATIONAL LAW; TUBERCULOSIS;

ARTICLE; HUMAN; HUMAN RIGHTS; LEGAL ASPECT; LUNG TUBERCULOSIS; METHODOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; PUBLIC HEALTH SERVICE; LEGISLATION AND JURISPRUDENCE; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; HUMAN RIGHTS; HUMANS; PUBLIC HEALTH ADMINISTRATION; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 67649462313     PISSN: 10790969     EISSN: None     Source Type: Journal    
DOI: 10.2307/20460107     Document Type: Article

References (24)

1. World Health Organization, The World Health Report 2004: Changing History (Geneva: WHO, 2004).
2. World Health Organization, Global Tuberculosis Control: Surveillance, Planning, Financing (Geneva: WHO, 2008).
3. M. A. Aziz et al., "Epidemiology of Antituberculosis Drug Resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): An Updated Analysis," Lancet 368 (2006), pp. 2142-2154.
4. For MDR-TB estimates, see M. Zignol et al., "Global Incidence of Multidrug-Resistant Tuberculosis," Journal of Infectious Diseases 194 (2006), pp. 479-485.
5. For data on the spread of XDR-TB in various regions of the world, see Centers for Disease Control and Prevention, "Emergence of Mycobacterium Tuberculosis with Extensive Resistance to Second-Line Drugs - Worldwide, 2000-2004," (MMWR) Morbidity and Mortality Weekly Report 55 (2006), pp. 301-305.
6. Finally, for mortality rates among HIV-infected patients diagnosed with XDR-TB, see N. R. Gandhi et al., "Extensively Drug-Resistant Tuberculosis as a Cause of Death in Patients Co-infected with Tuberculosis and HIV in a Rural Area of South Africa," Lancet 368 (2006), pp. 1575-1580.
7. World Health Organization, "Extensively Drug-Resistant Tuberculosis (XDR-TB): Recommendations for Prevention and Control," Weekly Epidemiological Record 81 (2006), pp. 430-432.
8. J. A. Singh, R. Upshur, and N. Padayatchi, "XDR-TB in South Africa: No Time for Denial or Complacency," PLoS Medicine 4 (2007).
9. See, for example, L. O. Gostin, Public Health Law: Power, Duty and Restraint (Berkeley, CA: University of California Press, 2000).
10. See, for example, M. K. Wynia, "Ethics and Public Health Emergencies: Restrictions on Liberty," The American Journal of Bioethics 7 (2007), pp. 1-5.
11. G. Trotter, The Ethics of Coercion in Mass Casualty Medicine (Baltimore, MD: Johns Hopkins University Press, 2007).
12. World Health Organization, WHO Guidance on Human Rights and Involuntary Detention for XDR-TB Control (January 24, 2007). Available at http://www.who.int/tb/xdr/involuntary_treatment/en/index.html.
13. Constitution of the World Health Organization, 14 U.N.T.S. 185 (1946)
14. International Covenant of Economic, Social and Cultural Rights, G.A. Res. 2200 (XXI), UN GAOR, 21st Sess., Supp. No. 16, at 49, UN Doc. A/6316 (1966) Art.12.
15. G. Pinet, Good Practice in Legislation and Regulations for TB Control: An Indicator of Political Will (Geneva: WHO, 2000). Available at http://whqlibdoc.who.int/hq/2001/WHO_CDS_TB_2001.290.pdf.
16. United Nations Economic and Social Council UN Sub-Commission on Prevention of Discrimination and Protection of Minorities: The Siracusa Principles on the Limitation and Derogation Provisions in the International Covenant on Civil and Political Rights, Annex (1985). U.N. Doc. E/CN.4/1985/4.
17. See, for example, Gostin (see note 7).
18. National Tuberculosis Controllers Association, Centers for Disease Control and Prevention, "Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC," MMWR Recommendations and Reports 54 / RR-15 (2005), pp. 1-47.
19. S. Etkind and J. Veen, "The Role of Contact Tracing in Low- and High-Prevalence Countries," in M. C. Raviglione (ed), Tuberculosis: A Comprehensive International Approach, (NY: Informa Healthcare USA, Inc., 3rd ed., 2006), pp. 555-581.
20. L. O. Gostin, R. Bayer, and A. L. Fairchild, "Ethical and Legal Challenges Posed by Severe Acute Respiratory Syndrome," Journal of the American Medical Association 290 (2003), pp. 3229-3237.
21. The Siracusa Principles (see note 12). 18. Gandhi et al. (see note 4).
22. The Siracusa Principles (see note 12).
23. L. O. Gostin and B. Berkman, Project on Addressing Ethical Issues in Pandemic Influenza Planning (Geneva: WHO, 2007). Available at http://www.who.int/eth/ethics/PI_Ethics_draft_paper_WG2_6_Oct_06.pdf.
24. A. Pablos-Mendez, C. A. Knirsch, R. G. Barr, B. H. Lerner, and T. R. Frieden, "Nonadherence in Tuberculosis Treatment: Predictors and Consequences in New York City," American Journal of Medicine 102 (1997), pp. 164-170.